**Momordica charantia** extracts ameliorate insulin resistance by regulating the expression of SOCS-3 and JNK in type 2 diabetes mellitus rats

Chunyu Ma\(^a\), Hongyu Yu\(^b\), Ying Xiao\(^a\) and Huijiao Wang\(^a\)

\(^a\)Department of Laboratory Diagnosis, Jinzhou Medical University, Jinzhou, PR China; \(^b\)Department of Basic Nursing, Jinzhou Medical University, Jinzhou, PR China

**ABSTRACT**

**Context:** *Momordica charantia* L. (Cucurbitaceae) has long been widely used as a traditional remedy for diabetes mellitus in some countries. However, detailed antidiabetic mechanisms are largely unknown.

**Objectives:** This study clarified the ameliorating effects of *M. charantia* ethanol extracts (MCE) on the insulin resistance in type 2 diabetes mellitus (T2DM) rats.

**Materials and methods:** T2DM rat model was established by high-fat diet and streptozotocin (STZ) injection. Diabetic rats were randomized into five groups: the model control group \((n = 8)\) (common diet), the high-fat diet metformin (50 mg/kg/d), and the three-dose MCE (100, 200, and 400 mg/kg/d) groups \((n = 8\) each). After 8 weeks, the fasting serum glucose, insulin, TNF-\(\alpha\), and IL-6 were measured, and the relevant factors of glucose and insulin were monitored by glycogen dyeing, RT-PCR, and western blot, respectively.

**Results:** The 8-week treatment of 400 mg/kg MCE significantly lowered body weight \((330.1\) versus \(365.9\) g), serum glucose \((7.41\) versus \(16.63\) mmol/L), insulin \((12.06\) versus \(15.89\) mIU/L), TNF-\(\alpha\) \((52.72\) versus \(81.83\) ng/L), and IL-6 \((104.81\) versus \(135.74\) ng/L) in comparison with those of the diabetic control group \((p < 0.05)\). It was the same for skeletal muscle glucose transporter 4 (GLUT-4) protein, and glycogen level, suppressor of cytokine signaling-3 (SOCS-3), c-Jun N-terminal kinase (JNK), and Akt expression at both protein and mRNA levels in liver \((p < 0.05)\).

**Conclusions:** MCE can ameliorate insulin resistance in T2DM rats. This effect may be related to the regulation of mRNA and protein levels of SOCS-3 and JNK.

**Introduction**

The incidence of diabetes mellitus has reached epidemic proportions worldwide and it will rise to more than 300 million people by 2025 (Adeghate et al. 2006). Among these patients with diabetes, 90–95% have type 2 diabetes mellitus (T2DM) (Chun et al. 2014). Therefore, the prevention and control of T2DM has become a major health care focus. Anti-diabetic treatments are grouped into diet, exercise, and drugs. Currently, the T2DM treatment drugs include insulin and anti-hyperglycaemic drugs, such as sulphonylurea derivatives, biguanides, and thiazolidinediones. Additionally, several herbal remedies provide a novel method to treat T2DM, which are characterized by fewer side effects and lasting moderate effect. *Momordica charantia* L. (Cucurbitaceae) has been used in the management of hyperglycaemia and early signs of diabetes since ancient times in some countries (Yin et al. 2008; Leung et al. 2009; Efird et al. 2014). It is effective and non-toxin for patients compared with other hypoglycaemic agents (Habicht et al. 2014) although, *M. charantia* extract (MCE) has hypolipidaemic (Chaturvedi et al. 2004), weight loss (Chen et al. 2003), and anti-inflammatory (Chao et al. 2014) activities.

Insulin resistance (IR) is the principal pathogenesis of T2DM as an independent risk factor. It occurs with the decreasing expression of hepatic glycogen and GLUT-4 in insulin-receptor-positive cells. Hepatic glycogen has the effect on the adjusting of blood glucose balance. GLUT-4 can transfer glucose from blood to tissue for utilization. However, IR resulted from abnormal insulin and downstream PI3K/Akt signal pathways, which can modulate glucose transport, glycogen synthesis, glycolysis, and protein synthesis (White 2002). Moreover, there are several inhibitory molecules for insulin-signalling pathway such as the protein tyrosine phosphatase 1B (PTP-1B), the suppressor of cytokine signaling-3 (SOCS-3), and c-Jun N-terminal kinase (JNK). However, such inflammatory signals as TNF-\(\alpha\) and IL-6 can activate inhibitory molecules such as SOCS-3 and JNK to suppress insulin-signalling pathway and cause IR (Kwon and Pessin 2013). Insulin receptor’s distribution density reduces in adipocyte and the typical pro-inflammatory cytokines such as TNF-\(\alpha\) and IL-6 are increased in the obese humans and rodents, suggesting that these factors could contribute to IR. These pro-inflammatory cytokines have the potential to exert negative effects on insulin sensitivity in an endocrine or paracrine manner. Therefore, T2DM has been proposed as a kind of inflammatory disease (Donath and Shoelson 2011; Lee and Lee 2014).

In this study, in order to clarify the hypoglycaemic effects and illuminate the ameliorating IR’s mechanism of MCE, fasting blood glucose and insulin levels were tested. The serum TNF-\(\alpha\) and IL-6 levels were also measured. Furthermore, the hepatic glycogen and the glucose transporter 4 (GLUT-4) expression were observed, and the insulin signal-related factors such as Akt-2,
PTP-1B, SOCS-3, and JNK's mRNA and proteins were also analyzed.

Materials and methods

The extract method of M. charantia ethanol extracts (MCE)

The mature green M. charantia were purchased from Jinzhou Darunfa super market in September 2012. This plant was taxonomically identified by Prof. Dr. Lijing Geng (College of Food Science, Jinzhou Medical University) and a voucher specimen (No. MC-120925) was deposited at the Herbarium of the College of Food Science, Jinzhou Medical University. The M. charantia fruits were washed thoroughly, and the seeds were removed. The pulp was cut into small pieces, dried, and smashed to powder, and then extracted with 70% ethanol (the ratio of material to solvent is 1–9) by 6 h. The ethanol extract was concentrated under the rotary evaporation, dried to solid by putting into freezer dryer, and then smashed to powder. The actual yield of MCE (freeze-dried powder versus dried weight of fruits) is 0.56%. The total saponins were identified by the vanillin-perchloric acid chromogenic method using ultraviolet spectrophotometer (UV-2550 type, Shimadzu, Japan). Ginsenoside Rg1 (MUST-13072505, Chengdu MUST Biological Technology Corporation, Chengdu, China) was selected as a reference substance and the absorbance was determined at 260 nm. Saponins content was calculated as the regression equation ($y = 0.0017x - 0.1745$). The total saponins content in MCE was 41.3%.

Experimental animals

All SPF-grade male SD rats (Liaoning Changsheng Corporation, Dalian, China, Animal license number: SCXK2010-0001) were purchased and housed in an air-conditioned room at 22 ± 3°C. All animal experiments were carried out in accordance with the National Research Council Guide for the Care and Use of Laboratory Animals.

Induction of T2DM rats and animal grouping

After a 1-week acclimation period, the rats were divided randomly into two groups. The control (CON) group ($n = 8$) was fed with common diet, whereas the experimental group ($n = 40$) was fed the high-fat diet (the standard fodder:sugar:lard:yolk = 60:17:20:3) for 8 weeks. After 8 weeks high-fat diet, the 25 mg/kg dose of streptozotocin (STZ, dissolved in 0.05 M citrate buffer at pH 4.5, prepared immediately before use, Sigma Corporation, St. Louis, MO) was injected through caudal vein in the experimental group rats as previously described (Spasov et al. 2007). One week after the STZ injection, rats were assessed by fasting blood glucose from the tail vein. The fasting blood glucose $\geq 11.1$ mmol/L was considered as a rat model of T2DM. Diabetic rats were fed with common diet and then were randomized into five groups: the model control group ($n = 8$), the metformin (Shandong Oriental Furuida Corporation, Dezhou, China) group ($n = 8$), and the three-dose MCE group ($n = 24$). The MCE group was administrated by oral gavage with MCE 100, 200, and 400 mg/kg/d for 8 weeks. The metformin group was administrated by gavage with metformin 50 mg/kg/d for 8 weeks. At the end of the experiment, the rats were sacrificed to collect blood in the tip of the heart under the condition of anaesthesia using 120 mg/kg pentobarbital sodium after the body weight was measured. At the same time, a part of liver and skeletal muscle tissue were dissected and frozen immediately at $-80^\circ$C.

Measurement of fasting serum parameters

The fasting serum glucose was measured by the automatic biochemical analyzer (7600-20 type, Hitachi High-Technologies, Tokyo, Japan). The levels of fasting serum insulin, TNF-α, and IL-6 were measured by ELISA using a commercial assay kit according to instructions from the manufacturer (rat insulin, TNF-α, and IL-6 ELISA kit, R&D Corporation, Minneapolis, MN). Homeostasis model of assessment-insulin resistance (HOMA-IR) was calculated by the following formula: fasting serum glucose (mmol/L) × fasting serum insulin (mIU/L)/22.5.

Hepatocyte glycogen analysis

Small pieces of liver tissue were fixed with neutral buffered formalin (200 g/kg) solution and embedded in paraffin for periodic Acid-Schiff staining (Nanjing Jiancheng Corporation, Nanjing, China). Under microscope (Olympus, Tokyo, Japan, BH53), the images were photographed at 10 (ocular) × 40 (object lens) magnification, and the average adipocyte area was computed with Image-Pro Plus 6.0 software (NIH Image J system, Bethesda, MD).

Reverse transcription-PCR analysis

The total RNA of liver from rats was isolated with a Trizol Reagent according to the instruction from the manufacturer. The total RNA was subjected to reverse transcription into cDNA in 100 µL reaction mixture. Polymerase chain reaction (PCR) was performed in a final 20 µL mixture using primer sequences under PCR conditions as listed in Table 1. The products were run on 2% agarose gels and stained with ethidium bromide. The relative density of the band was evaluated using Gene Genius Match systems software (BIO-RAD, Hercules, CA). The relative quantification results of gene expression were normalized on GAPDH.

Table 1. Primers used in this study.

| Gene   | Forward primer and reverse primer | Annealing temperature (°C) | PCR product (bp) | Accession number |
|--------|-----------------------------------|----------------------------|------------------|------------------|
| GAPDH  | F:5'-TCTCGGCCCCCTCCGCTGAT-3'     | 57                        | 291              | NM_017008       |
|        | R:5'-CCACGCCTTGAGACACCA-3'       |                           |                  |                  |
| Akt-2  | F:5'-ATGGAGCAGGACACCCCTGATG-3'   | 55                        | 167              | NM_017093       |
|        | R:5'-GTGGACTCTGCTCCCTCCTC-3'     |                           |                  |                  |
| PTP-1B | F:5'-TGGACGATGGGAAGCAGATG-3'     | 55                        | 133              | NM_012637       |
|        | R:5'-GGCGGTCTTCTGCTGCTC-3'       |                           |                  |                  |
| SOCS-3 | F:5'-ACAGGCCGGGCTTCTCAACA-3'     | 55                        | 450              | NM_053565       |
|        | R:5'-CTGGAGGCTCATGACTCGGTCC-3'   |                           |                  |                  |
| JNK    | F:5'-ATGTGAGTGGATCTGAGATG-3'     | 55                        | 182              | NM_053829       |
|        | R:5'-ATGTGCTTCTGCTGTTTAC-3'      |                           |                  |                  |
transcript levels. Results were expressed as the mean of three independent experiments performed in triplicate.

**Western blot analysis**

Skeletal muscle and liver samples were powdered with ultrasonic cell crush. Each homogenate (10 µL) was mixed with an equal amount of standard SDS sample loading buffer containing 0.25% bromophenol blue, and subjected to SDS-PAGE electrophoresis. After that, protein was transferred onto PVDF membrane by electroblotting. The membranes were then treated sequentially with blocking solution, and then with anti-GLUT-4, anti-Akt-2, anti-PTP-1B, anti-SOCS-3, or anti-JNK antibody (RD Inc, Minneapolis, MN). After washing, membranes were incubated with HRP-labelled secondary antibody (DAKO, Carpinteria, CA). Finally, electrochemiluminescence (ECL) was used to visualize the bands.

**Statistical analysis**

The results are presented as mean ± standard deviation. One-way analysis of variance (ANOVA) was used to determine the overall significant difference, and Fisher’s least significant difference (LSD) procedure was used to determine the significant differences between two groups. SPSS 17.0 statistical software (SPSS, Chicago, IL) was used for statistical analysis. $p < 0.05$ was considered as statistically significant.

**Results**

**Body weight**

As shown in Figure 1, before treatment, the body weight increased obviously in the model diabetic rats, compared with that in the control rats ($p < 0.01$). Compared with prior treatment, the body weight decreased in all diabetic rats after treatment, however, the body weight decreased obviously in Met ($p < 0.05$) and in MCE 200 mg ($p < 0.05$) and 400 mg ($p < 0.01$) groups, compared with that in T2DM model groups without treatment.

**Serum glucose, insulin, and HOMA-IR levels**

At the beginning and the end of the experiments, fasting serum glucose, insulin, and HOMA-IR are measured as shown in Figure 2. An obvious decrease in fasting serum glucose was observed in MCE group rats compared with T2DM rats ($p < 0.01$). Fasting serum insulin levels were elevated in the T2DM group compared with that from the control group; however, after 8 weeks treatment, MCE was expected to decrease these values in the treated diabetic group ($p < 0.05$). The result of HOMA-IR was as same as the fasting serum glucose.

**Liver glycogen content**

The liver glycogen presents fuchsia and the cell nucleus present blue by PAS dyeing (Figure 3). The effects of MCE on the liver
glycogen were seen to the figure. The fuchsia liver glycogen granule distributes equality in the normal control group. Through the Image-Pro Plus software analysis (NIH Image J system, Bethesda, MD), the liver glycogen granule's AOD value in the T2DM group was less than that of the CON group ($p < 0.01$), the liver glycogen granule's AOD value in 200 and 400 mg ($p < 0.01$) MCE group is more than that of the T2DM group, the same situation exists in the Met group; however, the value ($p < 0.05$) is lower than that of the 200 and 400 mg MCE group.

**Serum inflammatory factor**

As shown in Figure 4, the serum levels of TNF-α and IL-6 were higher in the T2DM than the CON groups ($p < 0.01$). Their levels decreased obviously in different MCE treatment

![Figure 3](image_url)
groups, compared with that in the T2DM group ($p < 0.05$ or $p < 0.01$). There was obviously significant difference among each MCE groups ($p < 0.01$) by using LSD statistic method.

**Reverse transcription PCR analysis**

Insulin signal pathway factor mRNA expression results are shown in Figure 5. In the untreated diabetic group, Akt-2 gene expression levels were significantly decreased compared with that from the control group ($p < 0.01$). After treatment of MCE, Akt-2 gene expression levels were significantly increased compared with that of the untreated diabetic group ($p < 0.01$). The mRNA expression of PTP-1B, SOCS-3, and JNK was increased obviously in the untreated diabetic group, compared with that from the normal group, and the expression level decreased obviously in all treatment groups, compared with that from the untreated diabetic group ($p < 0.05$ and $p < 0.01$). After 8 weeks treatment, the GLUT-4 protein level in different MCE groups was higher than that from the T2DM group ($p < 0.01$, Figure 6).

The p-Akt (Ser473) protein level was lower in the T2DM group than that from the normal group, but the protein level was increased obviously in MCE 200 and 400 mg groups, compared with that from the T2DM group ($p < 0.05$ and $p < 0.01$). The protein level of SOCS-3 and JNK was obviously higher in the T2DM group than that from the normal group ($p < 0.05$ and $p < 0.01$), but it was decreased obviously in all treatment groups compared with that from the T2DM group ($p < 0.05$ and $p < 0.01$), and the protein level decreased with the increasing dosage of MCE (Figure 7). The protein level of PTP-1B was increased obviously in the T2DM model group, compared with that from the normal group ($p < 0.01$).

**Discussion**

Obesity is a common inducement in IR. In our research, MCE has the effect of weight loss of diabetic rats, that is to say, MCE treatment can reduce the IR’s possibility of diabetic rats. Our findings confirmed that MCE could reduce the fasting serum glucose and insulin level in T2DM rats through 8 week’s treatment. The hypoglycemic effect of 400 mg MCE group was similar to metformin as reported previously (Miura et al. 2001). Because MCE treatment lowered the fasting serum insulin level, we speculate that the hypoglycemic effect of MCE is to ameliorate insulin resistance rather than stimulate the pancreatic β-cell to secret insulin. Nowadays, homeostasis model assessment insulin resistance (HOMA-IR) has become the common index to evaluate the insulin sensibility, insulin resistance level, and the function of pancreatic β-cell (Fujino et al. 2013). In our research, the HOMA-IR in T2DM rats was higher than the control group and decreased obviously after MCE treatment, indicating that MCE might obviously ameliorate insulin resistance.

After the meal, hepatic glycogen synthesis and storage is increased. When blood glucose was decreased because of too much utilization, hepatic glycogen is decomposed and released to increase the blood glucose, which is regulated by insulin, glucagon, adrenaline, etc. (Roach et al. 2012). In our study, the liver glycogen level in 200 and 400 mg MCE group is more than that of the T2DM group. This shows that MCE has the effect of increasing glycogen contents. Hazarika et al. (2012) found that MCE could prevent the phosphorylation of glycogen synthase kinase-3 (GSK-3) which might inhibit the activity of glycogen synthase and promote the synthesis of glycogen. Because the expression level of GLUT-4 can reflect the utilization degree of glucose, the promoting effects of MCE treatment on the GLUT4 expression demonstrated that MCE could decrease blood glucose by up-regulating GLUT expression, in line with previous reports (Chun et al. 2009; Kumar et al. 2009). The higher expression of GLUT-4 is the key factor for glucose utilization in peripheral tissue via the adenosine monophosphate-activated protein kinase (AMPK) pathway. MCE exerted anti-diabetic properties in HF-fed mice, also evidenced by a high AMPK phosphorylation and a low hepatic glucose production (Ojuka et al. 2002).

Reportedly, there are three Akt subtypes in mammals and Akt-2 deficiency showed the abnormal blood insulin and glucose. Akt activation caused glycogenesis, restraining glycogenolysis, restraining gluconeogenesis, and enhancing glucose oxidation and utilization (Sharma et al. 2015). The phosphorylation of Akt-2 at serine 473 is responsible for its activation (Tsuchiya et al. 2014) and employed to indicate the MCE effect on insulin signal transduction pathway. Here, the mRNA and protein expression
levels of Akt-2 were increased obviously in MCE groups, and increased with the dosage of MCE, suggesting that MCE might improve the insulin signal transduction through up-regulating the Akt-2 expression.

There are some important negatively regulatory proteins in the course of Akt’s activation, such as PTP-1B, SOCS-3, and JNK, whose down-regulation can weaken the inhibition effect of insulin and ameliorate IR. Some inflammatory factors (e.g. TNF-α and IL-6) can increase the mRNA expression of PTP-1B through NF-κB pathway (Yoshihiro et al. 2012), activate SOCS-3 (Shi et al. 2004), and JNK pathway (Choi et al. 2012). They finally influence the phosphorylation of insulin-sensitive cells, prevent the insulin signal transduction pathway, reduce the expression of GLUT-4, and then induce IR (Hashimoto et al. 2010; Kalupahana et al. 2012). In our studies, the treatment of MCE can decrease the serum TNF-α and IL-6 levels obviously, which gives another explanation about the inhibitory effects of MCE on IR.

PTP-1B is a member of protein tyrosine phosphatase family and its inhibition is the potential therapeutic way for obesity, insulin resistance, and T2DM (Koren and Fantus 2007). In our research, the mRNA expression amount of PTP-1B in MCE
groups was lower than in the T2DM group. However, the change of PTP-1B mRNA level was not related with the dosage of MCE and was inconsistent with the change of protein level, demonstrating that the effect of MCE on ameliorating IR was independent of PTP-1B’s expression. This may be associated with post-transcriptional control. SOCS family is a group of negative regulatory protein of cytokines through the central SH2 structural domain and conservative c-terminus box (Wormald and Hilton 2004). SOCS-3 can regulate the insulin sensibility through inhibiting tyrosine phosphorylation of insulin receptor substrate-1 and control insulin action and glucose homeostasis (Galic et al. 2014). The treatment of MCE decreased the mRNA and protein expression level of SOCS-3 with the increasing dosage of MCE. JNK is one of the members of mitogen-activated protein kinase (MAPK) family and widely participates in cell differentiation, apoptosis, immunoreactions, and IR. JNK overexpression can result in IR through the inhibition of insulin receptor substrate (IRS1): phosphatidylinositol 3-kinases (PI3K) signal transduction (Sharfi and Eldar-Finkelman 2008). Here, the treatment of MCE down-regulated the mRNA and protein expression level of SOCS-3 and JNK. This study can afford to the theoretical and experimental supports to exploit a new type of drug in T2DM personalized treatment.

Acknowledgements

This work was supported by Natural Science Foundation of Liaoning Province Science and Technology Department (Grant no. 20170540368) and Foundation of Liaoning Province Education Department (Grant no. L2012305).

Disclosure statement

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

Adeghate E, Schattner P, Dunn E. 2006. An update on the etiology and epidemiology of diabetes mellitus. Ann N Y Acad Sci. 1084:1–29.
Chao CY, Sung PJ, Wang WH, Kuo YH. 2014. Anti-inflammatory effect of Momordica charantia in sepsis mice. Molecules. 19:12777–12788.
Chaturvedi P, George S, Milinganyo M, Tripathi YB. 2004. Effect of Momordica charantia on lipid profile and oral glucose tolerance in diabetic rats. Phytother Res. 18:954–956.
Chen Q, Chan LL, Li ET. 2003. Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet. J Nutr. 133:1088–1093.
Choi JJ, Park MY, Lee HJ, Yoon DY, Lim Y, Hyun JW, Zouboulis CG, Jin M. 2012. TNF-α increases lipogenesis via JNK and PI3K/Akt pathways in SZ95 human sebocytes. J Dermatol Sci. 65:179–188.
Chun CS, Cheng HL, Wei LL, Wu JB. 2009. *Momordica charantia* extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats. J Ethnopharmacol. 123:82–90.

Chun CS, Min TS, Cheng HL, Jin BW. 2014. *Momordica charantia* ameliorates insulin resistance and dyslipidemia with altered hepatic glucose production and fatty acid synthesis and AMPK phosphorylation in high-fat-fed mice. Phytother Res. 28:363–371.

Donath MY, Shoelson SE. 2011. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 11:98–107.

Efird JT, Choi YM, Davies SW, Mehra S, Anderson EJ, Katunga LA. 2014. *Momordica charantia* Linn (Bitter melon) ameliorates insulin resistance and dyslipidemia with altered hepatic glucose production and fatty acid synthesis and AMPK phosphorylation in high-fat-fed mice. Phytother Res. 28:363–371.

Fujino H, Itoda S, Sako S, Sakamoto E, Yokoyama T. 2013. Potential for improved glycemic control with dietary *Momordica charantia* in patients with insulin resistance and pre-diabetes. Int J Environ Res Public Health. 11:2328–2345.

Fujino H, Itoda S, Sako S, Matsuo K, Sakamoto E, Yokoyama T. 2013. Reliability of HOMA-IR for evaluation of insulin resistance during perioperative period. Masui. 62:140–146.

Galic S, Sachithanandan N, Kay TW, Steinberg GR. 2014. Suppressor of cytokine signalling (SOCS) proteins as guardians of inflammatory responses critical for regulating insulin sensitivity. Biochem J. 461:177–188.

Habicht SD, Ludwig C, Yang RY, Krawinkel MB. 2014. *Momordica charantia* and type 2 diabetes: from *in vitro* to human studies. Curr Diabetes Rev. 10:48–60.

Hashimoto R, Sakai K, Matsumoto H, Iwashita M. 2010. Tumor necrosis factor-alpha (TNF-alpha) inhibits insulin-like growth factor-I (IGF-I) activities in human trophoblast cell cultures through IGF-I/insulin hybrid receptors. Endocr J. 57:193–200.

Hazarika R, Parida P, Neog B, Yadav RNS. 2012. Binding Energy calculation of GSK-3 protein of Human against some anti-diabetic compounds of *Momordica charantia* linn (Bitter melon). Bioinformation. 8:251–254.

Kalupahanca NS, Moustaid MN, Claycombe KJ. 2012. Immunity as a link between obesity and insulin resistance. Mol Aspects Med. 33:26–34.

Koren S, Fantus G. 2007. Inhibition of the protein tyrosine phosphatase PTP-1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus. Best Pract Res Clin Endocrinol Metab. 21:621–640.

Kumar R, Balaji S, Uma TS, Selgah PK. 2009. Fruit extracts of *Momordica charantia* potentiate glucose uptake and up-regulate Glut-4, PPP gamma and PI3K. J Ethnopharmacol. 126:533–537.

Kwon H, Pessin JE. 2013. Adipokines mediate inflammation and insulin resistance. Front Endocrinol (Lausanne). 4:71.

Lee BC, Lee J. 2014. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim Biophys Acta. 1842:446–462.

Miura T, Ioh C, Iwamoto N, Kato M, Kawai M, Park SR, Suzuki I. 2001. Hypoglycemic activity of the fruit of the *Momordica charantia* in type 2 diabetic mice. J Nutr Sci Vitaminol. 47:340–344.

Ojuka EO, Jones TE, Nolte LA, Chen M, Wamhoff BR, Sturek M, Holloszy JO. 2002. Regulation of GLUT4 biogenesis in muscle: evidence for involvement of AMPK and Ca2+. Am J Physiol Endocrinol Metab. 282:1008–1013.

Roach PJ, Depaoli RA, Hurley TD, Tagliabracci VS. 2012. Glycogen and its metabolism: some new developments and old themes. Biochim J. 441:763–787.

Sharfi H, Eldar-Finkelman H. 2008. Sequential phosphorylation of insulin receptor substrate-2 by glycogen synthase kinase-3 and c-Jun NH2-terminal kinase plays a role in hepatic insulin signaling. Am J Physiol Endocrinol Metab. 294:307–315.

Sharma BR, Kim HJ, Rhyu DY. 2015. *Caulerpa lentillifera* extract ameliorates insulin resistance and regulates glucose metabolism in C57BL/KsJ-db/db mice via PI3K/AKT signaling pathway in myocytes. J Transl Med. 13:62.

Shi H, Tramelli I, Bjorbaek C, Flier JS. 2004. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J Biol Chem. 279:34733–34740.

Soo JY, Jung MC, Se EP, Eun JR, Won YL, Ki WO, Sung WP, Cheol YP. 2015. Preventive effects of bitter melon (*Momordica charantia*) against insulin resistance and diabetes are associated with the inhibition of NF-xB and INK pathways in high-fat-fed OLETF rats. J Nutr Biochem. 26:234–240.

Spasov AA, Samokhina MP, Kheyfets IA, Duquina IL, Martyushov Pklov AD, Sergeeva SA, Epstein OI. 2007. Study of antidiabetic activity of a new ultralow-dose antibody preparation on the model of streptozotocin diabetes in rats. Bull Exp Biol Med. 144:46–48.

Tsuchiya A, Kanno T, Nishizaki T. 2014. PI3 kinase directly phosphorylates Akt1/2 at Ser473/474 in the insulin signal transduction pathway. J Endocrinol. 220:49–59.

Yoshihiro I, Ryoichi B, Shigeru H, Ozawa Y, Arima H, Oiso Y. 2012. TNFα increases hypothalamic PTP-1B activity via the NF xB pathway in rat hypothalamic organotypic cultures. Regul Pept. 174:58–64.

White MF. 2002. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab. 3:413–422.

Wormald S, Hilton DJ. 2004. Inhibitors of cytokine signal transduction. J Biol Chem. 279:821–824.